drugset / Trial / NCT04613271
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
Phase 3
Completed
130 enrolled
Ina-Respond
National Institute of Health Research and Development, Ministry of Health Republic of Indonesia · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The benefit of the research is to provide information regarding the efficacy and safety of Favipiravir plus the Standard of Care (SoC) for mild-moderate COVID-19 patients to be a reference for policy recommendations regarding the use of Favipiravir as an antiviral drug for the treatment of Covid-19.
Timeline
- Start
- 2020-10-15
- Primary completion
- 2021-10-25
- Completion
- 2021-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azithromycin | Small molecule | 500 mg | — |
| Subject | Favipiravir | Small molecule | 600 mg | — |